Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Olopade OI, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, Gyan KK, Altorki NK, Cheng E, Ginter PS, Hoda S, Newman L, Elemento O, Davis MB, Martin ML, Bargonetti J.
Madorsky Rowdo FP, et al. Among authors: boateng r.
bioRxiv [Preprint]. 2023 Jun 22:2023.06.22.544406. doi: 10.1101/2023.06.22.544406.
bioRxiv. 2023.
PMID: 38076873
Free PMC article.
Updated.
Preprint.